Trial Profile

Double-Blind, Randomized, Placebo-controlled, Safety and Efficacy Trial of BHV-3500 (Zavegepant) Intranasal for the Acute Treatment of Migraine

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 15 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

27 Apr 2023 Results presented at the 75th Annual Meeting of the American Academy of Neurology 2023
27 Apr 2023 Pooled data (N=2061) from NCT03872453, NCT04571060 presented at the 75th Annual Meeting of the American Academy of Neurology 2023.
27 Apr 2023 Results of post-hoc subgroup pooled analysis (N=2061; zavegepant n=1014, placebo n=1047) from NCT03872453 and NCT04571060 assessing the influence of attack frequency on the efficacy of zavegepant nasal spray in the acute treatment of migraine, presented at the 75th Annual Meeting of the American Academy of Neurology 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com